Axsome Therapeutics (AXSM) Current Leases (2020 - 2026)

Axsome Therapeutics has disclosed Current Leases across 7 years of filings, most recently posting $628000.0 for Q1 2026.

• Current Leases for Q1 2026 came in at $628000.0, down 65.42% year-over-year; the trailing twelve-month figure through Mar 2026 was $628000.0 (down 65.42% YoY), and the FY2025 annual result was $2.5 million, up 38.69% from the prior year.
• Current Leases came in at $628000.0 for Q1 2026 at Axsome Therapeutics, down from $2.5 million in the prior quarter.
• In the past five years, Current Leases ranged from a high of $2.5 million in Q4 2025 to a low of $108000.0 in Q1 2023.
• The 5-year median for Current Leases is $709120.0 (2022), against an average of $1.0 million.
• Across the five-year window, Current Leases slumped 88.83% in 2023 and surged 485.19% in 2024, its largest moves.
• Axsome Therapeutics' Current Leases stood at $425000.0 in 2022, then jumped by 198.12% to $1.3 million in 2023, then soared by 44.83% to $1.8 million in 2024, then soared by 38.69% to $2.5 million in 2025, then sank by 75.32% to $628000.0 in 2026.
• The last three Current Leases figures came in at $628000.0 (Q1 2026), $2.5 million (Q4 2025), and $2.5 million (Q3 2025), per Business Quant data.